Neurogene Inc. (NGNE)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 33.77 |
| Open | 33.10 |
| Bid | 35.26 x 100 |
| Ask | 35.67 x 100 |
| Day's range | 32.94 - 35.53 |
| 52-week range | 12.20 - 53.00 |
| Volume | |
| Avg. volume | 137,521 |
| Market cap | 455.317M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 48.33 |
Business WireNeurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK, April 22, 2024--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be presented at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting. The data show that the NGN-401 gene therapy candidate has been generally well-tol
- GuruFocus.com
Neurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023
Key Financials and Clinical Trial Updates Highlighted
Simply Wall St.With 32% ownership, Neurogene Inc. (NASDAQ:NGNE) has piqued the interest of institutional investors
Key Insights Significantly high institutional ownership implies Neurogene's stock price is sensitive to their trading...
© 2024 Yahoo. All rights reserved.